Evidence map›Paper›PMID 27499390›Full record

ArticleScientific reports2016

Targeted alternative splicing of TAF4: a new strategy for cell reprogramming.

Jekaterina Kazantseva, Helle Sadam, Toomas Neuman, Kaia Palm

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jekaterina KazantsevaProtobios LLC, Tallinn, Estonia.
Helle SadamProtobios LLC, Tallinn, Estonia.
Toomas NeumanProtobios LLC, Tallinn, Estonia.
Kaia PalmProtobios LLC, Tallinn, Estonia.
Protobios (Estonia) · EETallinn University of Technology · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reprogramming of somatic cells has become a versatile tool for biomedical research and for regenerative medicine. In the current study, we show that manipulating alternative splicing (AS) is a highly potent strategy to produce cells for therapeutic applications. We demonstrate that silencing of hTAF4-TAFH activity of TAF4 converts human facial dermal fibroblasts to melanocyte-like (iMel) cells. iMel cells produce melanin and express microphthalmia-associated transcription factor (MITF) and its target genes at levels comparable to normal melanocytes. Reprogramming of melanoma cells by manipulation with hTAF4-TAFH activity upon TAFH RNAi enforces cell differentiation towards chondrogenic pathway, whereas ectoptic expression of TAF4 results in enhanced multipotency and neural crest-like features in melanoma cells. In both cell states, iMels and cancer cells, hTAF4-TAFH activity controls migration by supporting E- to N-cadherin switches. From our data, we conclude that targeted splicing of hTAF4-TAFH coordinates AS of other TFIID subunits, underscoring the role of TAF4 in synchronised changes of Pol II complex composition essential for efficient cellular reprogramming. Taken together, targeted AS of TAF4 provides a unique strategy for generation of iMels and recapitulating stages of melanoma progression.

Indexed as

Cellular ReprogrammingAlternative SplicingCadherinsCell DifferentiationCell LineCell MovementDermisFibroblastsHumansMelanocytesMicrophthalmia-Associated Transcription FactorMicroscopy, FluorescenceNeoplastic Stem CellsRNA InterferenceRNA, Small InterferingTATA-Binding Protein Associated FactorsCadherinsMicrophthalmia-Associated Transcription FactorRNA, Small InterferingTAF4 protein, humanTATA-Binding Protein Associated FactorsTranscription FactorsTranscription Factor TFIID

Identifiers

PMID27499390
PMCPMC4976350
OpenAlexW2536551695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.